Home > Insider Trading > Filing (0000899243-22-037475)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1404955	Loring Seth Harrison	C/O Akero Therapeutics, Inc., 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-11-30	6,322	$46.44	141,080	No	4	S	Direct
Common Stock	Disposition	2022-11-30	4,779	$47.60	136,301	No	4	S	Direct
Common Stock	Disposition	2022-11-30	6,851	$46.44	153,242	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-11-30	5,179	$47.60	148,063	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.28 to $47.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.29 to $47.93, inclusive.
Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.